Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.
TransCode Therapeutics, Inc. develops RNA and immuno-oncology therapeutics for high-risk and advanced cancers. News about RNAZ centers on its lead candidate TTX-MC138, an antagomiR targeting microRNA-10b, along with preclinical publications, IND-related clinical updates, research collaborations and sponsored research tied to RNA-targeted oncology.
Company updates also cover additions to its early-stage oncology pipeline, including adenovirus-based oncolytic immunotherapy candidates UIO-524, UIO-525 and UIO-526, as well as governance changes involving its board and scientific advisory structure. Capital-structure announcements, material agreements and operating or financial results are recurring disclosure themes for this clinical-stage biotechnology issuer.
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has signed a non-binding letter of intent and a joint research and development agreement with BRAIN Biotech AG to co-develop a platform technology aimed at cancer treatment. The partnership focuses on integrating BRAIN's G-dase E CRISPR nuclease with TransCode's TTX nucleic acid delivery platform. This innovative approach targets cancer cells based on RNA biomarkers, potentially leading to new therapeutic applications. The collaboration is considered a significant milestone for TransCode, expanding its pipeline and enhancing its methodologies for treating metastatic cancer, which causes a majority of cancer-related deaths globally.
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) announced a registered direct offering of 2,846,300 shares at $0.527 per share, aiming to raise approximately $1.5 million in gross proceeds. H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around February 17, 2023, subject to standard conditions. The shares are being offered via a previously filed shelf registration statement with the SEC. This capital raise is intended to support the development of TransCode's RNA therapeutic candidates targeting various cancer types, including metastatic cancers, which are responsible for significant cancer mortality worldwide.
TransCode Therapeutics (Nasdaq: RNAZ) announced successful preclinical proof-of-mechanism studies for its immunotherapy candidate, TTX-RIGA, in melanoma, designed to activate innate immunity via RIG-I receptor binding. The studies showed promising results in delivering RNA-based agonists to tumors, potentially enabling tumor-selective immune responses. The company plans to advance TTX-RIGA to animal studies in February 2023. Furthermore, FDA has authorized a Phase 0 clinical trial for another candidate, TTX-MC138, targeting microRNA-10b in advanced solid tumors, with patient enrollment expected soon.
TransCode Therapeutics (NASDAQ: RNAZ) has received FDA authorization to commence its First-in-Human (FIH) Phase 0 clinical trial for TTX-MC138, targeting advanced solid tumors in up to 12 cancer patients. TTX-MC138 aims to inhibit microRNA-10b, a key player in metastasis. The trial will assess the delivery of the therapeutic to metastatic lesions and gather crucial pharmacokinetic data. Preclinical results indicate TTX-MC138's potential effectiveness in various cancers, demonstrating complete responses in animal studies. This marks a significant advancement for TransCode as a clinical-stage oncology company.
TransCode Therapeutics (NASDAQ: RNAZ) has withdrawn its Registration Statement on Form S-1, initially filed on November 28, 2022, due to unfavorable market conditions. The Company believes these conditions do not align with the best interests of its stockholders for a public offering. TransCode focuses on RNA-based cancer treatments, aiming to improve patient outcomes with its therapeutic candidates targeting various tumor types. Their lead candidate, TTX-MC138, aims to treat metastatic cancer, a leading cause of cancer deaths worldwide.
TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an exploratory eIND application to the FDA for a First-in-Human Phase 0 clinical trial of TTX-MC138, targeting advanced solid tumors. This therapeutic aims to inhibit microRNA-10b, a key player in metastasis. The trial will involve up to 12 patients to assess the safety and pharmacokinetics of TTX-MC138. Successful results could pave the way for further clinical trials and potential treatments for aggressive cancers like breast and pancreatic cancer.
TransCode Therapeutics (NASDAQ: RNAZ) reported Q3 2022 financial results, highlighting significant advancements in its RNA oncology pipeline. The company remains on schedule to submit an exploratory IND application for a Phase 0 trial involving TTX-MC138 in advanced solid tumors. Recently granted orphan drug designation for TTX-siPDL1 for pancreatic cancer emphasizes its focus on high-need areas. Financially, cash reserves decreased to $8.8 million, while R&D expenses surged to $3 million, reflecting ongoing investment in therapeutic development. The company expects funding will last through Q1 2023.
TransCode Therapeutics (RNAZ) announced positive preclinical results for its immunotherapy candidate TTX-siPDL1 in treating pancreatic adenocarcinoma. After two weekly treatments with TTX-siPDL1 and gemcitabine, tumor volumes were significantly reduced, with 75% of treated animals surviving compared to 25% for gemcitabine alone. The study demonstrated effective PD-L1 inhibition and immune activation. CEO Michael Dudley highlighted the platform's capability to overcome challenges in RNA delivery within tumors, marking a significant opportunity for the company.
TransCode Therapeutics (Nasdaq: RNAZ) has announced its participation in the Sidoti Virtual Investor Conference on November 9-10, 2022. CEO Michael Dudley will present the company's advancements in RNA-based therapies targeting metastatic cancer, including its lead candidate TTX-MC138, which is entering first-in-human clinical trials. The presentation is scheduled for 2:30 pm ET on November 9 and will be available via webcast. TransCode aims to innovate cancer treatment through RNA therapeutics and has developed multiple candidates addressing various tumors.
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) reported positive preclinical results for its lead candidate TTX-MC138 in treating pancreatic adenocarcinoma. The murine study showed a 40% complete response rate with treated mice and a successful pharmacodynamic response demonstrated by down-regulation of microRNA-10b. Further studies are underway to optimize dosing. TTX-MC138 has previously shown efficacy in breast cancer models, and the company plans to file an exploratory Investigational New Drug application for a Phase 0 clinical trial later this year.